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In their report, Götte and coworkers [1] analyzed the
expression of c-Met in 200 patients with ductal carcinoma in
situ. They concluded that c-Met could be related to
angiogenic and lymphangiogenic factors in ductal carcinoma
in situ. On the other hand, Greenberg and coworkers [2]
studied 31 patients with ductal infiltrating carcinoma (DIC) to
detect c-Met expression in their axillary fluids. They observed
a correlation of c-Met expression with increasing tumor size
and grade, capillary and lymphatic invasion and lymph node
metastasis.
We applied the fluorescent in situ hybridization (FISH)
technique using the LSI D7S486/CEP7 commercial probe
(Abbott Molecular Inc., Des Plaines, IL, USA), which includes
the  MET gene, and immunohistochemistry using c-Met
monoclonal antibody clone 3D4 (Invitrogen, Carlsbad, CA,
USA) to 184 archival invasive breast tumors (93 DIC and 91
lobular carcinomas). We constructed ten tissue microarrays
with three replicates per sample. Pearson’s chi-squared and
Fisher’s exact test were used to analyze the results.
None of the 155 breast tumors analyzed by FISH presented
amplification of MET and 35 cases (22%) had a low grade of
polysomy (three to five copies) of chromosome 7. Polysomy
was more frequently observed in DIC (25%; P = 0.001). We
tried to correlate polysomy of MET in the DIC group with
grade, tumor size, lymph node status, clinical stage and
expression of HER2, P53, estrogen receptor (ER) and
progesterone receptor (PR). We observed that the absence
of expression of PR was the unique statistically significant
variable (P = 0.001). Moreover, the ER+/PR- samples
presented the highest rate of polysomy (38%) compared to
ER+/PR+ tumors (15%) (Table 1).
Out of 168 tumors analyzed by immunohistochemistry, 65
(38.7%) presented expression of c-Met. When histological
types were compared, the DIC group also showed the
highest number of c-Met-positive samples (48%; P = 0.001).
From the analysis with the clinico-pathological variables, the
negativity for PR was again statistically significant (P = 0.001).
The ER+/PR- tumors presented more frequent expression of
c-Met (68%) compared to ER+/PR+ tumors (32%) and were
correlated with polysomy (P = 0.020) (Table 2).
We can conclude that amplification of MET in breast cancer
is not a common event, as opposed to other cancer subtypes
(renal, gastric and lung carcinomas). Although found in breast
tumors, it seems that overexpression of c-Met is not mainly
due to increassed gene copy number of MET/polysomy7.
However, polysomy in the ER+/PR- group could be an
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important mechanism - although not the only one -
responsible for the differential expression observed in this
type of DIC. This c-Met overexpression and the presence of
polysomy 7 could be important events to be considered with
regard to the known poor response to endocrine therapies of
ER+/PR- breast tumors. Lack of PR expression in ER+
tumors may be a surrogate marker of aberrant growth factor
signaling [3] that could be associated with their more
aggressive outcome, as has already been described [4].
Our study suggests that it would be interesting to investigate
new therapeutic options for ER+/PR- DIC, which may include
c-Met inhibitors.
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Table 1
Results of IHC of c-Met and FISH of LSI D7S486/CEP7 applied to lobular and ductal carcinomas
IHC c-Met FISH MET FISH + IHC
Negative Positive Negative Polysomy PE + P
Carcinoma type
Lobular 57 (76%) 18 (24%) 61 (81%) 15 (19%) 5 (7%)
Ductal (DIC) 42 (52%) 38 (48%) 60 (75%) 20 (25%) 13 (16%)
DIC type
ER+/PR+ 31 (68%) 15 (32%) 39 (85%) 7 (15%) 3 (6%)
ER+/PR- 11 (32%) 23 (68%) 21 (62%) 13 (38%) 10 (29%)
DIC, ductal infiltrating carcinoma; PE, positive expression; ER, estrogen receptor; FISH, fluorescent in situ hybridization; IHC,
immunohistochemistry; P, polysomy; PR, progesterone receptor. In bold we remark the positive FISH and IHQ results for DIC as well as for
ER+/PR- tumors
Table 2
IHC and FISH results of MET according to the status of PR
receptor in DIC carcinomas
ER+/PR+ (n= 46) ER+/PR- (n = 34)
IHC IHC IHC IHC
FISH MET Negative Positive Negative Positive
FISH Negative 27 (59%) 12 (26%) 9 (23%) 13 (38%)
FISH Polysomy 4 (9%) 3 (6%) 3 (9%) 10 (29%)
DIC, ductal infiltrating carcinoma; ER, estrogen receptor; FISH,
fluorescent in situ hybridization; IHC, immunohistochemistry; P,
polysomy; PR, progesterone receptor. In bold we remark the FISH and
IHQ positive results to compare both groups.